ClinicalTrials.gg
RecruitingNCT05414292RapamuneUpdated Apr 10, 2025

Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)

An interventional study of Rapamune (sirolimus) 1Mg Tablet and Unilateral resistance exercise training in Muscle Atrophy and Age-Related Sarcopenia, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to male participants aged 50 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by University of Nottingham · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2021, registered May 2022).
  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Muscular Atrophy by University of Nottingham — 3 open to participants now, 5 under way, none of them phase 3. Muscular Atrophy · University of Nottingham.

Started
2021
with 1 other
No phase
7 of 11
3 open now
Registered
8th of 11
by date

Among the 11 studies in Muscular Atrophy by University of Nottingham, this one is one of 2 that started in 2021, is one of 7 with no phase, and was the 8th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

3 of the 11 studies in Muscular Atrophy by University of Nottingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 50 Years to 90 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Muscular Atrophy by University of Nottingham, or all of them as a file.
02

Study summary

As people age, muscle mass and function is lost and exercise training is an important way to reduce the effects of this and remain independent. However, not everyone can perform this exercise and the muscle responses to exercise are often reduced in older people. So far there has been no drug found to specifically treat or reduce this problem.

Muscle size depends on the balance of muscle protein breakdown and synthesis (building). This balance is regulated by multiple signals within the body, but a particular molecule - the mechanistic target of rapamycin (mTOR), is known to play an important role. For protein synthesis to build up the muscles, this pathway is needed to start the process when triggered by eating protein or exercise. Although this would suggest that mTOR activity is good, excessive levels of this signalling seem to have negative impacts on muscle maintenance with age.

In animal studies, blocking mTOR signalling has stopped the development of a number of age-related diseases and increased health-span. Drugs that block this pathway (e.g. Rapamune) reduce the stimulation of muscle protein synthesis, possibly through changing the immune system, but conversely have also been shown to increase muscle size and reduce markers of nerve supply loss. This means that drugs which block the mTOR pathway could, in older people, help to reduce the negative impacts of excessive mTOR signalling on muscle size and function.

The investigators aim to recruit 16 healthy male volunteers over 50 years old to investigate how the drug Rapamune (which blocks the mTOR pathway) affects aged human muscle both on its own and when combined with resistance exercise training.

Read the detailed description

Skeletal muscle is known for its role in locomotion however, muscles are also important for maintaining whole-body metabolic health. Skeletal muscles represent a vast protein store, the amino acids from which can be broken down in times of fasting, infection and disease in order to provide energy and amino acids to maintain other critical organs. With increases in the ageing population, this will inevitably increase age-related co-morbidities, and also the prevalence of frailty and increased healthcare costs.

A major facet of frailty is skeletal muscle atrophy and loss of function, and critically, these are associated with poorer clinical outcomes (e.g. surgery), so mitigating age-related muscle loss is crucial for healthy ageing. The processes of muscle loss with ageing in humans are a combination of neurodegeneration of lower motor neurons and concomitant muscle fibre atrophy. While the underlying mechanisms of age-related muscle loss are unclear, a reduced responsiveness to key environmental cues, namely nutrition and movement ("anabolic resistance"), would appear to be central. To date, no pharmaceuticals have yielded the necessary safety and efficacy effects to mitigate age-related muscle loss so exercise, particularly resistance exercise training (RET), remains the most established intervention to improve muscle mass and function in older people. Nonetheless, not all older people can perform RET, and muscle growth responses to RET are diminished in older age. As such, the search for interventions to mitigate muscle ageing and maximise responses to exercise pre-/rehabilitation in terms of muscle growth and function remain key.

The mechanistic target of rapamycin (mTOR) is often termed a "master regulator" in relation to skeletal muscle homeostasis and exists in two distinct complexes, mTORc1 and mTORc2. The most established role of mTORc1 in muscle is as a cellular sensor of nutrients and movement, where signals are conveyed to mTOR substrates, regulating the rate of mRNA translation and thus muscle protein synthesis (MPS). mTOR activity is required for the stimulation of MPS by intake of dietary proteins or free amino acids, in addition to contractile activity, and as such is commonly thought of as being positive in relation to muscle mass. Additionally, administration of rapamycin (a naturally occurring compound that inhibits mTORc1) alongside exercise or nutrient-intake has been shown to reduce the stimulation of MPS. However, confounding the notion of a positive role of mTOR on skeletal muscle, hyper-activation of mTOR has been shown in both ageing rodent and human muscle, suggesting that mTOR signalling has negative impacts in relation to muscle maintenance in ageing.

Despite the positive effects of mTOR in relation to the stimulation of MPS, in animal models data suggest that pharmacological attenuation of mTOR signalling can counteract several age-related diseases and co-morbidities, and increase overall health-span. The major negative ageing traits found to be lessened by dampening mTOR signalling (i.e. with rapamycin) are related to the immune system, organ morphology, neo-plastic disease and neurological dysfunction e.g. motor control. From these studies, the beneficial effects of rapamycin on health-span are clear, but this contrasts the positive impacts mTOR signalling have on muscle. Inhibition of mTOR would be predicted to negatively impact muscle protein turnover however, this is not the case.

Indeed, recent work has challenged the notion of mTOR suppression negatively impacting skeletal muscle metabolism in a number of experimental settings. In pre-clinical models of ageing and/or muscle dysfunction, long-term administration of rapamycin did not negatively impact skeletal muscle mass in mice treated with rapamycin across the life-course. Additionally, long-term administration of rapamycin (9-22 months), showed a mitigation of muscle mitochondrial ageing, reflected by markers of mitochondrial DNA genome stability. Perhaps the most compelling evidence of rapamycin benefiting ageing muscle is from a study where rapalog (a rapamycin analog) treatment was administered to mice where hyper-active mTOR signalling was observed in aged sarcopenic animals, as is also shown in older humans. Crucially, following Rapalog treatment animals demonstrated increases in muscle fibre area in addition to a down-regulation of cellular senescence markers and genes associated with neuromuscular denervation. These works challenge the notion that in older age with mTOR hyper-activation, mTOR-inhibition would have negative effects, and it is now accepted that ageing and age-associated diseases that arise from hyperactive mTORC1 signalling may benefit from mTOR inhibitors. As such, insight into the effects of mTORc1 inhibition are needed in humans, especially in the context of "anabolic resistance", which limits both muscle maintenance and growth potential in older adults. As an immunosuppressant, rapamycin may also present benefits for the treatment of COVID-19 which is a current highly important area of emerging research.

In this study the participant will have muscle size, function and metabolism measured over a 16 week period while either taking the drug Rapamune or a placebo. They will also complete 14 weeks of unilateral resistance exercise with visits described below.

  1. Pre-study Assessment

    Twenty-four hours before attending their main pre-study assessment, participants will be asked to consume the labelled creatine (D3-labelled; Cre) and (D3) methylhistidine (3-MH) tracers.. In order to trace these tracers into urine and plasma body pools respectively, participants will be asked to provide a urine sample before consuming these tracers (which they will bring with them the following day), and the blood sample from screening will be used for 3-MH analysis to minimise participant burden. In the 24-hours between consuming the tracer drink and attending for their pre-study assessment participants will be asked to collect all urinary output for which containers will be provided. Participants will also be asked to collect spot urine samples at \~48 amd 72-hours after consuming the tracer drink.

    For their main pre-study assessment, participants will be randomly assigned to either a rapamycin inhibitor (Rapamune) or placebo (matching benign capsule containing sugar to achieve as equal weight and appearance to the treatment product as possible) group (single-blind), and will report to the laboratory for their pre-study assessment day. A suite of baseline assessments will then be performed including body composition (e.g. MRI and muscle ultrasound to determine lean mass, fat mass, muscle thickness, cross-sectional area (CSA) and muscle architecture) and measures of muscle strength and function (1-RM, MVC, power, SPPBT and iEMG). These measures will be repeated throughout the intervention period to monitor temporal changes. Throughout this visit, 6 venous blood samples (\~5 ml) will be taken for the assessment of muscle protein breakdown (MPB) via the 3-MH tracer consumed the previous day.

    At the end of their pre-study assessment visit, participants will begin a two week lead-in phase of Rapamune or placebo capsules. On day 13-15 of this lead-in phase, participants will attend the laboratory for their muscle biopsies (\~150 mg each), which will be collected from the vastus lateralis (VL) of both legs (rest and exercise). This bilateral biopsy collection will allow volunteers to act as their own controls by providing both an exercise trained leg and a rested leg; to also compare the effects of Rapamune combined with contractile stimulus. Biopsy sites will be closed by sutures, which are removed (and the wound site checked) after 5-7 days. After these initial biopsies, participants will be given their bolus dose of D2O to begin assessing rates of MPS. To minimise the risk of dizziness from D2O consumption, this initial dose will be split into 6-8 smaller does provided throughout the day. Two hours after their final D2O dose, participants will be asked to provide a saliva sample..

  2. Resistance exercise training (RET) RET consisting of unilateral knee-extension exercise (i.e. 6 × 8 repetitions at 75% of one repetition maximum (1-RM)) will be performed 3 x each week 14-weeks.The RET will be progressive, with reassessment of 1-RM being performed at regular intervals to maintain exercise intensity. Participants will also be provided with their interventional drug (for daily dosing) and D2O tracer top-ups (for the assessment of MPS) on a weekly basis during these visits, with a venous blood sample also collected weekly. Participants will be asked to collect daily saliva samples for the first week (\~2h after D2O consumption), and on a weekly basis thereafter.
  3. Mid-study Assessment 1 After 3-weeks of RET, all of the baseline procedures from the pre-study assessment visits will be repeated, with the exception of the measures relating to the D3 and 3-MH tracers, and MRI which will not be performed on this visit.
  4. Mid-study Assessment 2 After 6-weeks of RET, all of the baseline procedures from the pre-study assessment visits will be repeated. No further D2O will be given or saliva samples collected after week 6 of RET.
  5. Post-study Assessment After 14-weeks of RET, all of the baseline procedures from the pre-study assessment visits will be repeated. The label of the creatine will be 13C instead of D3 to permit a second analysis of whole body muscle mass.
03

Conditions studied

  • Muscle Atrophy
  • Age-Related Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the study
  • Participant is physically able to complete the resistance exercise training programme

Exclusion criteria

Exclusion Criteria:

    • A \<18 or >35 kg/m2

      • Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, , pulmonary hypertension or recent stroke
      • Any metabolic disease
      • Clotting dysfunction
      • A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)
      • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (this must remain for ALL UoN FMHS UREC approved studies)
      • to MRI scanning including claustrophobia, pacemaker, metal implants etc. which will be assessed through an MRI safety screening questionnaire.
      • Contraindications to the use of Rapamycin e.g. those due scheduled vaccinations (as rapamycin can reduce the efficacy of vaccines).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Drug group

    Will take 1mg Rapamune (sirolimus) in oral tablet form daily for 16 weeks.

    Drug: Rapamune (sirolimus) 1Mg Tablet · Behavioral: Unilateral resistance exercise training

  • Placebo comparator
    Placebo group

    Will take a placebo tablet (lactose) daily for 16 weeks

    Behavioral: Unilateral resistance exercise training

Interventions

  • DrugSirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.

    Also known as: Rapamycin, Sirolimus, Rapamune

  • BehavioralUnilateral resistance exercise training

    Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum

    Also known as: Leg extension, Strength training

06

What researchers measure

Primary outcomes

  1. Change in muscle mass from baseline

    To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles.

    Time frame: 0 and 16 weeks

  2. Change in muscle mass from baseline

    To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles.

    Time frame: 0 and 8 weeks

  3. Change in muscle mass from baseline

    To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles.

    Time frame: 0 and 5 weeks

Secondary outcomes

  1. Change in muscle strength

    To determine the impacts of rapamycin on muscle function through muscle strength measures of 1 Repetition Maximum

    Time frame: 0, 5, 8 and 16 weeks

  2. Change in muscle power

    To determine the impacts of rapamycin on muscle function through muscle power measured from countermovement jump analysis.

    Time frame: 0, 5, 8 and 16 weeks

  3. Change in muscle function

    To determine the impacts of rapamycin on muscle function through muscle performance measures included in the short performance physical battery test (SPPBT).

    Time frame: 0, 5, 8 and 16 weeks

  4. Change in neuromuscular function

    • To determine the impacts of rapamycin on muscle function through muscle-nerve electrical signals studied with electromyography (EMG).

    Time frame: 0, 5, 8 and 16 weeks

  5. Change in Muscle Protein Synthesis

    To determine the impacts of rapamycin on muscle metabolism through effects on muscle protein synthesis (via D2O tracer) from muscle biopsies.

    Time frame: 2, 5, and 8 weeks

  6. Change in Muscle Protein Breakdown

    To determine the impacts of rapamycin on muscle metabolism through effects on muscle protein breakdown (via 3-MH tracer) obtained from muscle biopsies.

    Time frame: 2 and 16 weeks

  7. Immune function

    Collection of peripheral blood mononuclear cells to study the immune cytokine profile using an Isoplexis system

    Time frame: 0, 2, 5, 8 and 16 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Nottingham School of Medicine
    Derby, DE22 3DT, United Kingdom
    Recruiting
    • Philip Atherton · Contact
    • Philip Atherton, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data may be shared with collaborators including anthropometric data and samples where consent is given for this.

Supporting information: Study protocol, Analytic code

Time frame: The data will be available on conclusion of the study.

Access criteria: Listed collaborators will have access on request with data given on approval by the principal investigator

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for May 2027, 68 months after the start.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 68 months is above that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 10, 2022
StartActual
Aug 6, 2021
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05414292
Responsible party
Philip Atherton (Professor, University of Nottingham) — Principal investigator
First posted
Jun 10, 2022
Start date
Aug 6, 2021
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Apr 10, 2025

Study contacts

Philip Atherton, PhD
Contact
philip.atherton@nottingham.ac.uk
01332724725

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion